[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"epigenetic-aging\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:epigenetic-aging":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,91],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100572976","the-impact-of-an-evidence-based-parenting-service-on-maternal-sensitivity-and-infant-cellular-aging-in-a-population-of-under-resourced-families-100572976",false,"NCT06740266","The Impact of an Evidence-Based Parenting Service on Maternal Sensitivity and Infant Cellular Aging in a Population of Under-Resourced Families","The Impact of Stress and Caregiver Sensitivity on Infant Cellular Aging in a Population of Under-Resourced Families: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Biological mother of infant aged 3-12 months English- or Spanish-speaking Receiving Medicaid Their infant is receiving pediatric care at WakeMed\n\nExclusion Criteria:\n\n* Experiencing an acute crisis (e.g. hospitalization, incarceration) Homeless or without stable enough housing for home visits Lacking access to a phone Previously received the Promoting First Relationships intervention",true,"FEMALE","18 Years",{"count":20,"type":21},250,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial study is to learn how stress in childhood, or Early Life Adversity (ELA), gets \"under the skin\" and influences long-term health. The investigators will test if the support given to parents of young children reduces childhood stress. The investigators will also test if the effects of mother's stress and Early Life Adversity can be passed down to children. Can it impact the child's long-term health? Researchers will compare the Promoting First Relationships® in Primary Care (PFR in PC) parenting program with Usual Care to see if PFR reduces mothers' stress, improves mother's sensitivity, and reduces accelerated cellular aging.\n\nParticipants will:\n\n* Be randomized to receive PFR in PC or Usual Care. PFR in PC is an evidence-based 10-week home visiting service, with 2 extra sessions at the WakeMed pediatric clinic. Usual Care is the health care and general services offered to families at the WakeMed pediatric clinic.\n* Have in-home research visits at the start of the study (Time 1, T1), about 6 months later (Time 2, T2), and 12 months later (Time 3, T3). Information collected at these visits includes:\n\n  * Answering questions about your background, past and current stress, physical and mental health, parenting behaviors, and child behavior problems (T1, T2, T3).\n  * Being videotaped doing a short teaching activity.\n  * Having a small amount of blood collected from the mother by finger prick (T1, T3).\n  * Having a small amount of blood collected from the infant by heel stick (T1, T3).",[27,28,29,30],"Parent Child Relationship","Child Social-Emotional Development","Telomere Length","Epigenetic Aging",[32,33,34,35],"Epigenetic aging","Parenting intervention","Parent sensitivity","Pediatric setting","RECRUITING","2026-02-04",{"date":39,"type":40},"2026-02-06","ACTUAL",{"date":42,"type":40},"2024-12-13",{"date":44,"type":21},"2029-04",{"name":46,"class":47},"University of Washington","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":16,"sex":56,"minAge":4,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":68,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":48},"100612570","follow-up-study-of-varapodio-trial-effect-of-longevity-and-fasting-mimicking-diet-on-risk-factors-age-correlated-and-biomarkers-of-aging-100612570","NCT07255300","Follow up Study of Varapodio Trial: Effect of Longevity and Fasting Mimicking Diet on Risk Factors Age Correlated and Biomarkers of Aging","Follow up Study of the Effects of the Longevity and the Fasting Mimicking Diet on Body Composition, Age-related Risk Factors and Biomarkers of Aging in a Randomized Study 1 and 2","Inclusion Criteria:\n\nSubjects of 30-65 years of age;\n\nExclusion Criteria:\n\nindividuals with a family member already included in the study; individuals who are allergic to tree nuts (macadamia, cashew, almond, pecan), soy, oats, sesame, or celery\u002Fceleriac; pregnant females; Individuals with any documented cancer diagnosis within the past 5 years; documented myocardial infarction within past 5 years; documented cerebrovascular accident within past 5 years; chronic steroid use (longer than 45 consecutive days); insulin-dependent diabetes mellitus; individuals taking insulin or insulin-like drugs and individuals taking hypoglycemic agents other than metformin. In this last case, close attention will therefore be paid to the self-monitoring of blood glucose during the FMD cycles; Individuals with severe hypertension (systolic greater than 200 mmHg and or diastolic greater than 105 mmHg.\n\nChange in prescription medications, over-the-counter (OTC) medications, medical foods, and nutritional supplements within 30 days prior to the start and for the duration of the study.\n\nUse of medications classified as narcotics 15 days prior start and for the duration of the study.\n\nUse of prescription medications and\u002For over-the-counter medications for acute and semi- acute medical conditions 15 days prior to start and for the duration of the study.\n\nUse of acetaminophen is permitted on an as-needed basis. Use of an investigational drug or participation in an investigational study within 30 days prior to the start and for the duration of the study.\n\nUse of oral or injectable corticosteroids within 30 days prior to the start and for the duration of the study.\n\nUse of anticoagulant medications (heparin compounds or warfarin) within 30 days prior to the start and for the duration of the study. Use of aspirin 81 mg or 325 mg once daily is permitted.\n\nUse of neuroactive prescription medications including major and atypical antipsychotic medications, anti-depressants, anti-anxiolytics, and epilepsy medications within 30 days prior to the start and for the duration of the study.\n\n(subjects will not be allowed to discontinue prohibited prescription medications to meet enrolment criteria).\n\nA history of allergy or intolerance to study products. Detailed descriptions of study product are included in Section 4.1 and 4.2, appended to the Study Informed Consent.\n\nClinically significant vital sign abnormalities (systolic blood pressure \\\u003C90 mmHg or \\>200 mmHg, diastolic blood pressure \\\u003C50 mmHg or \\>105 mmHg or resting heart rate of \\\u003C50 or \\>100 bpm) at screening visit.\n\nA serious, unstable illness including cardiac, hepatic, renal, gastrointestinal, respiratory, endocrinologic, neurologic, immunologic, or hematologic disease.\n\nKnown infection with HIV, TB or Hepatitis B or C.\n\nA current diagnosis or personal history of:\n\nAny cardiovascular disease including myocardial infarction, angina, cardiovascular surgery (within 5 years), congestive heart failure, cardiac arrhythmias or conduction abnormalities, cerebrovascular accident, transient ischemic attack (TIA), or peripheral vascular disease, deep vein thrombosis or pulmonary embolus. Diabetes mellitus requiring inhaled or injected insulin.\n\nAny autoimmune disease such as inflammatory bowel disease (including Crohn's disease and\u002For ulcerative colitis), multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, polymyositis, scleroderma and\u002For thyroiditis.\n\nAny significant liver or kidney disease such as cirrhosis or non-alcoholic fatty liver disease, glomerulonephritis, and\u002For ongoing dialysis treatment.\n\nAny malignancy (with the exception of adequately treated malignancies with no known recurrence for \\>2 years).\n\nAny serious mental illness including a history of attempted suicide. Any medical condition that in the opinion of the primary care doctor or a specialist would preclude safe participation in this study or interfere with compliance.\n\nUse of drugs of abuse (such as marijuana, cocaine, phencyclidine \\[PCP\\] and methamphetamine) 15 days prior to Day 1 and for the duration of the study.\n\nHistory of regular intake of \\>14 alcoholic drinks per week for females, and \\>21 drinks per week for males (1 drink = 35 cl. beer, 12 cl. wine, or 30 ml. hard liquor).\n\nTechnical reasons\n\nAny condition in which bioelectrical impedance testing would be impossible or uninterpretable (e.g. prostheses in extremities on both sides, limb amputation, implanted pacemaker, inability to lay still or supine, or skin defects on preferred electrode placement sites.\n\nOther Exclusion Criteria: Inability to comply with study and\u002For follow-up visits.\n\nAny concurrent condition (including clinically significant abnormalities in medical history, physical examination or laboratory evaluations) which, in the opinion of the PI, would preclude safe participation in this study or interfere with compliance.\n\nAny sound medical, psychiatric and\u002For social reason which, in the opinion of the PI, would preclude safe participation in this study or interfere with compliance.\n\nAbnormal laboratory findings including: abnormal blood counts (hematocrit \\\u003C 33% or \\> 47%; WBC \\\u003C 3.0 or \\> 12.0 x10\\^3\u002Fmm3; platelets \\\u003C 140 or \\> 500 x 10\\^9\u002FL); abnormal kidney function test (creatinine \\> 2.5 mg\u002FdL) or liver function test(s) (AST, ALT, alkaline phosphatase) \\> 1.5X the upper limit of normal; serum calcium \\> 11 mg\u002FdL); serum K \\\u003C 3.5 mEq\u002FL; Na \\\u003C 134 or \\> 148 mmolL-1 Women of Childbearing Potential Contraception: the effects of the study products on the developing human fetus have not been studied extensively. For this reason, women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Females of childbearing potential will have a pregnancy test prior to receiving study products. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform study staff and her primary care physician immediately.\n\nPregnancy: because there is an unknown but potential risk for adverse events in pregnant women during treatment with the study products, pregnant women are not eligible for study participation.\n\nBreast-feeding: Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with the study products, breastfeeding mothers are not eligible for study participation.","ALL",{"count":58,"type":21},135,[24],"A large ongoing randomized, open-label trial aimed at evaluating the effects of two different dietary interventions, FMD and LD, on body composition and cardiovascular (CV) biomarkers in a real word population (NCT05698654) is actually ongoing. This trial started in January 2024 will enrol 501 adult subjects between the ages of 30 and 65: 167 subjects randomized to the FMD arm with a 5-day meal program once every three months for a 6-month period (arm 1); 167 subjects randomized to follow the FMD plus a Longevity Diet program (FMD+LD) for a 6-month period (arm 2); 167 randomized to the control group (arm 3) that will continue their usual diet. On 2024,410, participants were enrolled and randomly assigned to FMD, FMD + LD, or control arm. Although preliminary data demonstrated the beneficial effects of such nutritional plans on body weight, BMI, body composition, and cardiovascular (CV) biomarkers, limited data is available on the long-term effects of these powerful nutritional interventions.",[62,63,30,64,65,66,67],"Fat Mass","Risk Factors Cardiovascular Disease","Metabolism Changes","Overweight (BMI > 25)","Risk Behavior","Obesity (Disorder)",[69,70,71,72,73,74,75,76,77,78,79,80,81,62],"fasting","fasting mimicking diet","Longevity Diet","Longevity","Diet","Aging","FMD","Nutrition","Diseases","LD","Clinical Trial","Randomized","Health","2025-11-20",{"date":84,"type":40},"2025-12-01",{"date":86,"type":40},"2025-05-02",{"date":88,"type":21},"2027-06-02",{"name":90,"class":47},"Fondazione Valter Longo",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":16,"sex":56,"minAge":98,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":22,"phases":102,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":48},"100391336","phase-2-thymus-regeneration-immunorestoration-and-insulin-mitigation-extension-trial-100391336","NCT04375657","Thymus Regeneration, Immunorestoration, and Insulin Mitigation Extension Trial","TRIIM-X","Inclusion Criteria:\n\n* Male or female volunteers\n* Aged 40 to 80 years, inclusive\n* All ethnicities\n* Able to participate in 12-month study\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Malignancies or high risk of malignancy, as suggested by familial risk or personal medical history\n* Premenopausal women\n* Postmenopausal women on HRT\n* IGF-1 levels \\\u003C 90 ng\u002Fml or \\>300 ng\u002Fml\n* Diagnosed or suspected growth hormone resistance\n* Known growth hormone deficiency based on stimulation testing\n* Pre-existing carpal tunnel syndrome\n* Significant arthritis\u002Farthralgia\u002Fjoint swelling\n* Bradycardia (\\\u003C55 bpm), significant hypertension (systolic \\>160 mmHg, or diastolic \\>90 mmHg) despite treatment, serious angina, or other serious cardiovascular disease or cardiovascular disease risk factors\n* Excessive skin growths (e.g., flat warts) without cryosurgical options\n* BMI of 35 or greater\n* PSA level above the age-adjusted normal range for reasons other than confirmed prostatitis\n* Testosterone levels above the upper limit of normal\n* Levels of C-reactive protein (CRP) above the upper limit of normal\n* Type 1 or pre-existing Type 2 diabetes\n* Uncorrected hypothyroidism\n* HIV infection\n* Allergy or other sensitivity to study medications\n* Other unstable medical conditions\n* Use of GH within the last 5 years\n* Participation in a clinical research trial within 30 days prior to enrollment\n* Use of chronic glucocorticoid therapy\n* Unwilling to discontinue androgen supplementation if testosterone levels are above the upper limit of normal\n* Ongoing treatment with carbonic anhydrase inhibitors\n* Ketogenic diet, calorie-restricted diet, or prolonged fasting, without willingness to discontinue these diets or adhere to an alternative diet during the study\n* Alcoholism or drug addiction\n* Smoking or unwillingness to quit smoking\n* Cognitive impairment, illiteracy, inability or unwillingness to give voluntary informed consent","40 Years","80 Years",{"count":101,"type":21},85,[103],"PHASE2","The TRIIM-X trial is an expanded pilot clinical study that will evaluate a personalized combination treatment regimen for thymus regeneration. The thymus is a part of the immune system that declines markedly with age, and regenerating it may prevent or reverse key aspects of immunosenescence (immune system aging) and potentially prevent or reverse key parts of the aging process more generally. The study will evaluate biomarkers for epigenetic aging and immunosenescence, as well as evaluate established clinical measures and risk factors for prevention of physical frailty, cancer, cardiovascular disease, diabetes, dementia, and also infectious diseases, including flu and COVID-19.\n\nThe study uses multiple agents in combination with personalized doses of recombinant human growth hormone (somatropin), metformin, and DHEA, in a similar manner to how the combination treatment was applied in the earlier TRIIM trial at Stanford, which demonstrated strong statistical significance for the primary efficacy endpoints that will be evaluated in TRIIM-X. Somatropin is approved by the FDA for adult growth hormone deficiency and its use in the study is guided by prior safety data established for that use and also based on safety data available on its prior use in the TRIIM trial and in clinical practice in healthy elderly individuals. There will also be control groups that enable testing of biomarker variability and the contribution of individual medications within the combination treatment.\n\nThe objective of the study is to obtain information needed for designing an effective personalized and adaptive treatment regimen for a larger and more diverse study population, and to obtain additional proof of principle for the new use of the medications and biomarkers for preventive medicine. The duration of treatment in the TRIIM-X trial will be 12 months.",[30,106],"Immunosenescence","2025-05-05",{"date":109,"type":40},"2025-05-07",{"date":111,"type":40},"2020-11-23",{"date":113,"type":21},"2025-12",{"name":115,"class":116},"Intervene Immune, Inc.","INDUSTRY"]